Changes in the expression and methylation levels of the MMP-2, MMP-9, TIMP-1, TIMP-2 and VEGF-A genes in children with acute lymphoblastic leukemia
Öz
Purpose: The aim of this article is to show the expression and methylation levels of matrix metalloproteinases (MMPs), tissue inhibitors of metalloproteinases (TIMPs) and vascular endothelial growth factor (VEGF)genes in patients diagnosed with childhood acute lymphoblastic leukemia (ALL) and their relationship with clinical findings.
Materials and Methods: In this study, we determined the expression level and methylation percentage of MMP2, MMP9, TIMP1, TIMP2 and VEGF-A genes between patients with childhood ALL and healthy children. Expression and methylation analyzes were performed by RT-PCR. The results of MMP2, MMP9, TIMP1, TIMP2, VEGF-A and other clinical parameters were compared between the two groups.
Results: The expression levels of MMP2 (2.55-fold), MMP9 (5.06-fold), TIMP1 (2.91-fold) and VEGF-A (4.76-fold) was significantly higher in the patients, but the same results were not found for TIMP-2. The methylation levels of MMP2 (29.74%), MMP9 (30.98%), TIMP2 (11.91%) and VEGF-A (6.55%) were significantly higher in the patients than in the controls.
Conclusion: MMP2, MMP9 and VEGF-A genes have high expression and methylation levels. These results make this complex structure intriguing in childhood ALL for further studies and reinforce the emphasis that it should be investigated.
Anahtar Kelimeler
Acute lymphoblastic leukemia, MMP, TIMP, VEGF-A
Destekleyen Kurum
This work was supported by Çukurova University Scientific Research Projects Unit
Proje Numarası
TF2012D1
Teşekkür
We would like to thank the Scientific Research Unit of Çukurova University for supporting our project.
Kaynakça
- Board, PPTE. Childhood acute lymphoblastic leukemia treatment (PDQ). In PDQ Cancer Information Summaries [Internet]. National Cancer Institute (US). 2019.
- Marech I, Leporini C, Ammendola M, Porcelli M, Gadaleta CD, Russo E, et al. Classical and non-classical proangiogenic factors as a target of antiangiogenic therapy in tumor microenvironment. Cancer letters. 2016;380(1):216–226.
- Medinger M, Passweg J. Role of tumour angiogenesis in haematological malignancies. Swiss medical weekly. 2014;144:w14050.
- Perez-Atayde AR, Sallan SE, Tedrow U, Connors S, Allred E, Folkman J. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. The American journal of pathology. 1997;150(3):815–821.
- Poyer F, Coquerel B, Pegahi R, Cazin L, Norris V, Vannier JP, et al. Secretion of MMP-2 and MMP-9 induced by VEGF autocrine loop correlates with clinical features in childhood acute lymphoblastic leukemia. Leukemia research. 2009;33(3):407–417.
- Rundhaug JE. Matrix metalloproteinases and angiogenesis. Journal of cellular and molecular medicine. 2005;9(2):267–285.
- Lin CM, Zeng YL, Xiao M, Mei XQ, Shen LY, Guo MX. The Relationship Between MMP-2 -1306C>T and MMP-9 -1562C>T Polymorphisms and the Risk and Prognosis of T-Cell Acute Lymphoblastic Leukemia in a Chinese Population: A Case-Control Study. Cellular physiology and biochemistry: international journal of experimental cellular physiology, biochemistry, and pharmacology. 2017;42(4):1458–1468.
- Scrideli CA, Cortez MA, Yunes JA, Queiróz RG, Valera ET, da Mata JF, et al. mRNA expression of matrix metalloproteinases (MMPs) 2 and 9 and tissue inhibitor of matrix metalloproteinases (TIMPs) 1 and 2 in childhood acute lymphoblastic leukemia: potential role of TIMP1 as an adverse prognostic factor. Leukemia research. 2010:34(1);32–37.
- Salah NY. Vascular endothelial growth factor (VEGF), tissue inhibitors of metalloproteinase-1 (TIMP-1) and nail fold capillaroscopy changes in children and adolescents with Gaucher disease; relation to residual disease severity. Cytokine. 2020;133:155120.
- Padró T, Ruiz S, Bieker R, Bürger H, Steins M, Kienast J, et al. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood. 2000;95(8):2637–2644.
